
This study sought to investigate the efficacy and safety of gimsilumab, an anti–GM-CSF monoclonal antibody, to treat hospitalized patients with elevated inflammatory markers and hypoxemia secondary to COVID-19. The gimsilumab and placebo groups experienced an all-cause mortality rate at Day 43 of 28.3% and 23.2%, respectively. Gimsilumab did not improve mortality or other key clinical outcomes in patients with COVID-19 pneumonia and evidence of systemic inflammation. The utility of anti–GM-CSF therapy for COVID-19 remains unclear.
Like
Save
Share